fda compounding semaglutide crackdown news november 2025 Drug compounders sue over declaration ending Wegovy shortage How FDA Crackdowns Are Affecting

References J Physiol 1905

Julie Cunningham, MPH, RDN, LDN, CDCES Medical Reviewer Julie Cunningham is a registered dietitian-nutritionist and a certified diabetes care and education specialist

Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al

One study showed that acute and chronic treatment with MPH in the SHR model increased oxidative stress [136]

You'll encounter less marketing noise and more focus on actual treatment outcomes